ELEVIDYS
Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty
Sarepta Therapeutics; debt maturity extension; convertible notes; private placement; Elevidys; financial strategy; biopharma
Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns
Sarepta Therapeutics; Elevidys; Q2 2025; gene therapy; sales performance; FDA; safety issues; shipment pause
Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027
Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline
Untangling Sarepta’s Gene Therapy Fallout and Trust Deficit
Sarepta Therapeutics; gene therapy; Elevidys; Duchenne muscular dystrophy; limb-girdle muscular dystrophy; patient deaths; FDA; AAVrh74 vector; regulatory action; clinical holds; transparency
FDA Reverses Course, Allows Sarepta to Resume Duchenne Gene Therapy Shipments
FDA; Sarepta Therapeutics; Duchenne muscular dystrophy; Elevidys; gene therapy; safety pause; shipment resumption
FDA Investigates Elevidys Death; Sarepta and Roche Deny Link to Gene Therapy
FDA; Elevidys; Sarepta Therapeutics; Roche; gene therapy; Duchenne muscular dystrophy; patient death; Brazil; market suspension; safety concerns
CHMP Recommends Against Approval of Elevidys Gene Therapy in Europe, Dealing Blow to Sarepta and Roche
CHMP; Elevidys; Sarepta; Roche; gene therapy; Duchenne muscular dystrophy; EMA; negative opinion; Europe; EMBARK trial
FDA Official Says Sarepta Faces Major Hurdles to Reintroduce DMD Therapy Elevidys
Sarepta; Elevidys; FDA; Duchenne muscular dystrophy; gene therapy; CBER; safety concerns; shipment pause; new studies; approval status
Roche Halts Elevidys Distribution in Several Countries Following Sarepta and FDA Safety Concerns
Roche; Sarepta Therapeutics; Elevidys; Duchenne muscular dystrophy; gene therapy; FDA; shipment halt; safety concerns; patient deaths
Sarepta Halts US Shipments of Duchenne Therapy Elevidys After FDA Pressure
Sarepta Therapeutics; Elevidys; Duchenne muscular dystrophy (DMD); FDA; gene therapy; safety concerns; shipment suspension; patient deaths